Seagen Stock Forecast, Price & News

Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

How has Seagen's stock price been impacted by Coronavirus?

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 43.1% and is now trading at $149.55.
View which stocks have been most impacted by COVID-19.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Seagen.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $1.05. The biotechnology company earned $424.60 million during the quarter, compared to the consensus estimate of $384.83 million. Seagen had a negative trailing twelve-month return on equity of 9.88% and a negative net margin of 19.06%. The business's revenue for the quarter was down 60.0% compared to the same quarter last year. During the same period last year, the firm earned $3.50 EPS.
View Seagen's earnings history.

What price target have analysts set for SGEN?

13 brokers have issued 1-year price objectives for Seagen's shares. Their forecasts range from $145.00 to $254.00. On average, they anticipate Seagen's stock price to reach $184.36 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:

• Clay B. Siegall, Chairman, President & Chief Executive Officer
• Todd E. Simpson, Chief Financial Officer
• Vaughn B. Himes, Chief Technical Officer (LinkedIn Profile)
• Roger D. Dansey, Chief Medical Officer (LinkedIn Profile)
• Natasha A. Hernday, Executive Vice President-Development

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Seagen's key competitors?

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of SGEN's competitors.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.70%), Wellington Management Group LLP (6.67%), Primecap Management Co. CA (2.64%), Geode Capital Management LLC (0.91%), Invesco Ltd. (0.87%) and Franklin Resources Inc. (0.79%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen.

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., Toronto Dominion Bank, Primecap Management Co. CA, Martingale Asset Management L P, International Biotechnology Trust PLC, and Schonfeld Strategic Advisors LLC. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Marshall Wace LLP, Invesco Ltd., Artal Group S.A., Jennison Associates LLC, ANTIPODES PARTNERS Ltd, Voya Investment Management LLC, and BlackRock Inc..
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $149.55.

How much money does Seagen make?

Seagen has a market capitalization of $27.35 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,092 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

Where are Seagen's headquarters?

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.